By NewsDesk  @infectiousdiseasenews Commercial stage biopharmaceutical company, Zai Lab Limited, announced today dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial...

A new study has found that the majority of residents in a rural village of Vietnam harbored multi-drug-resistant (MDR), colistin-resistant E. coli bacteria. Colistin is typically used as a last-resort...

Colistin is used as the “last-resort antibiotic” for dreaded multidrug-resistant pathogens, especially in hospitals. However, gut bacteria that have become insensitive to colistin now exist...

The Los Angeles County Department of Public Health (Public Health) announced the identification of the first mcr-1 producing bacteria found in a Los Angeles County resident. This isolate of the bacteria...

The mcr-1 gene–a gene that makes bacteria resistant to colistin, an antibiotic of last resort, and that is transferrable between bacteria–has been found in a wide variety of strains of Escherichia...

Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that its lead product candidate,...

On the occasion of the 9th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) is releasing its latest EU-wide data on antibiotic resistance and antibiotic...

The Centers for Disease Control and Prevention is part of a coordinated public health response after the Department of Defense (DoD) announced the discovery of the first mcr-1 gene found in bacteria in...

In January 2016, the Lancet confirmed what the medical world has been dreading: a bacterial organism with essentially unfettered protection against all the antibiotics available to control it has been...

The European Medicines Agency (EMA) has received a request from the European Commission to update its advice on the use in animals of colistin, which is one of the last-resort antibiotics to treat certain...